An Open Label Phase IIa Clinical Study to Evaluate the Safety and Pharmacokinetics of Intravenous and Oral F901318 (Combined With Caspofungin) for Antifungal Prophylaxis in Patients Undergoing Chemotherapy for Acute Myeloid Leukaemia
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 19 Feb 2018
At a glance
- Drugs Caspofungin (Primary) ; F 901318 (Primary) ; F 901318 (Primary)
- Indications Aspergillosis
- Focus Adverse reactions
- Acronyms SAFEGUARD
- Sponsors F2G
- 13 Feb 2018 Planned primary completion date changed from 1 Mar 2017 to 21 Apr 2017.
- 13 Feb 2018 Planned initiation date changed from 1 Sep 2016 to 20 Apr 2017.
- 13 Feb 2018 Planned End Date changed from 1 May 2017 to 22 Apr 2017.